Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Clinical Significance of the IL-33-ACOD1-MARCO Axis in HBV-Related Acute-on-Chronic Liver Failure

15 listopada 2026 zaktualizowane przez: Minghui Li

The IL-33-ACOD1-MARCO Axis in Ameliorating Immune-Mediated Liver Injury and Its Clinical Significance in HBV-Related Acute-on-Chronic Liver Failure

This single-center, prospective observational study will enroll 80 adults: 15 healthy controls, 20 participants with chronic hepatitis B, 20 participants with HBV-related cirrhosis, and 25 participants with HBV-related acute-on-chronic liver failure (HBV-ACLF). The study will not assign any research treatment, and all participants will continue to receive routine clinical care. A 5 mL peripheral blood sample will be collected once from the first three groups. Participants with HBV-ACLF will have 5 mL blood collected at baseline, Day 28, and Day 90, and their 28-day and 90-day survival status will be recorded. Plasma IL-33, IL-6, TNF-alpha, and IL-10 will be measured. Peripheral blood CD14-positive monocytes will be isolated, and ACOD1 and MARCO mRNA expression will be measured by quantitative PCR. The study will compare these markers across groups and assess their relationships with inflammation, disease severity, longitudinal clinical changes, and short-term outcomes.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Szczegółowy opis

HBV-related acute-on-chronic liver failure is characterized by rapid clinical deterioration, systemic inflammation, and high short-term mortality. Previous experimental work in a mouse model of immune-mediated liver injury suggested that IL-33 may induce ACOD1 expression in hepatic macrophages and increase MARCO expression through an itaconate-related pathway, thereby enhancing efferocytosis and reducing inflammatory injury. The complete IL-33-ACOD1-MARCO axis has not been established in patients, and measurements in peripheral blood CD14-positive monocytes cannot be considered direct measurements of liver-resident macrophage function.

This study combines a cross-sectional comparison with longitudinal follow-up. At baseline, plasma IL-33 and inflammatory cytokines and CD14-positive monocyte ACOD1 and MARCO mRNA expression will be compared among healthy controls, participants with chronic hepatitis B, participants with HBV-related cirrhosis, and participants with HBV-ACLF. In the HBV-ACLF group, associations with Model for End-Stage Liver Disease (MELD) score, COSSH-ACLF score, IL-6, TNF-alpha, and IL-10 will be evaluated. Participants with HBV-ACLF will undergo follow-up at Day 28 and Day 90 to assess biomarker changes, all-cause mortality, and liver transplantation status.

Blood will be collected in EDTA-K2 tubes and processed within 2 hours. Plasma IL-33 will be measured by ELISA, and IL-6, TNF-alpha, and IL-10 will be measured by Luminex. Peripheral blood mononuclear cells will be isolated by Ficoll density-gradient centrifugation, followed by CD14-positive magnetic-bead selection and flow-cytometric verification of purity. ACOD1 and MARCO mRNA expression will be measured by quantitative PCR using GAPDH as the reference gene and the 2^-DeltaDeltaCt method.

Typ studiów

Obserwacyjny

Zapisy (Szacowany)

80

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Beijing Municipality
      • Beijing, Beijing Municipality, Chiny, 100015
        • : Beijing Ditan Hospital, Capital Medical University
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 70 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie dotyczy

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Adults aged 18 to 70 years will be recruited at Beijing Ditan Hospital, Capital Medical University. The study population will include healthy individuals undergoing routine health examinations and patients receiving care at the Liver Disease Center for chronic hepatitis B, HBV-related cirrhosis, or HBV-related acute-on-chronic liver failure. Individuals who meet the applicable group definition and the inclusion and exclusion criteria will be enrolled after providing written informed consent. The planned enrollment is 15 healthy controls, 20 participants with chronic hepatitis B, 20 participants with HBV-related cirrhosis, and 25 participants with HBV-ACLF.

Opis

Inclusion Criteria:

  • Aged 18 to 70 years, regardless of sex.
  • Meets the criteria for one of the following study groups:

Healthy Control Group: No history of liver disease, negative hepatitis B surface antigen (HBsAg), and normal liver function.

Chronic Hepatitis B Group: HBsAg positivity for more than 6 months, no imaging evidence of cirrhosis, and does not meet the diagnostic criteria for HBV-related acute-on-chronic liver failure (HBV-ACLF).

HBV-Related Cirrhosis Group: HBsAg positivity for more than 6 months and cirrhosis confirmed by imaging or pathological examination, without meeting the diagnostic criteria for HBV-ACLF.

HBV-ACLF Group: HBsAg positivity for more than 6 months and meets the COSSH-ACLF diagnostic criteria.

-Fully understands the study and voluntarily provides written informed consent.

Exclusion Criteria:

  • Coinfection with hepatitis A, C, D, or E virus, or the presence of another liver disease, including autoimmune liver disease, drug-induced liver injury, or alcohol-related liver disease.
  • Confirmed hepatocellular carcinoma.
  • Pregnancy or breastfeeding.
  • Treatment with immunosuppressive agents or high-dose glucocorticoids within 4 weeks before enrollment.
  • Human immunodeficiency virus infection.
  • Severe renal impairment, defined as an estimated glomerular filtration rate below 30 mL/min/1.73 m².
  • Incomplete key clinical data at enrollment or an anticipated inability to complete the study sampling and follow-up required for the assigned group.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Modele obserwacyjne: COHORT
  • Perspektywy czasowe: PROSPECTIVE

Kohorty i interwencje

Grupa / Kohorta
Healthy Control

Adults without a history of liver disease, with negative hepatitis B surface antigen and normal liver function. Participants will undergo one study blood collection at enrollment.

Chronic Hepatitis B

Adults with hepatitis B surface antigen positivity for more than 6 months, without imaging evidence of cirrhosis and not meeting the COSSH-ACLF diagnostic criteria. Participants will undergo one baseline study blood collection.

HBV-Related Cirrhosis

Adults with chronic HBV infection and cirrhosis confirmed by imaging or pathology, without meeting the COSSH-ACLF diagnostic criteria. Participants will undergo one baseline study blood collection.

HBV-Related Acute-on-Chronic Liver Failure

Adults with hepatitis B surface antigen positivity for more than 6 months who meet the COSSH-ACLF diagnostic criteria. Participants will undergo study blood collection at baseline, Day 28, and Day 90 and will be followed for 28-day and 90-day survival outcomes.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Plasma IL-33 Concentration at Baseline Across Study Groups
Ramy czasowe: Baseline (at enrollment or hospital admission)

Plasma IL-33 concentration will be measured in EDTA plasma by enzyme-linked immunosorbent assay (ELISA) in healthy controls, participants with chronic hepatitis B, participants with HBV-related cirrhosis, and participants with HBV-related acute-on-chronic liver failure.

Baseline (at enrollment or hospital admission)
ACOD1 mRNA Expression in Peripheral Blood CD14-Positive Monocytes at Baseline Across Study Groups
Ramy czasowe: Baseline (at enrollment or hospital admission)

Peripheral blood mononuclear cells will be isolated and CD14-positive monocytes will be selected using magnetic beads. ACOD1 mRNA expression will be measured by quantitative PCR, with GAPDH as the reference gene, and reported as relative expression calculated using the 2^-DeltaDeltaCt method.

Baseline (at enrollment or hospital admission)
MARCO mRNA Expression in Peripheral Blood CD14-Positive Monocytes at Baseline Across Study Groups
Ramy czasowe: Baseline (at enrollment or hospital admission)

Peripheral blood mononuclear cells will be isolated and CD14-positive monocytes will be selected using magnetic beads. MARCO mRNA expression will be measured by quantitative PCR, with GAPDH as the reference gene, and reported as relative expression calculated using the 2^-DeltaDeltaCt method.

Baseline (at enrollment or hospital admission)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Correlation of Plasma IL-33 With ACOD1 and MARCO mRNA Expression in Participants With HBV-ACLF
Ramy czasowe: Baseline

At baseline in participants with HBV-related acute-on-chronic liver failure, Spearman correlation coefficients will be calculated between plasma IL-33 concentration and ACOD1 and MARCO mRNA relative expression in peripheral blood CD14-positive monocytes.

Baseline
Association of ACOD1 and MARCO mRNA Expression With Disease Severity and Inflammatory Markers in Participants With HBV-ACLF
Ramy czasowe: Baseline

At baseline in participants with HBV-related acute-on-chronic liver failure, correlations of ACOD1 and MARCO mRNA relative expression with Model for End-Stage Liver Disease (MELD) score, COSSH-ACLF score, plasma IL-6, TNF-alpha, and IL-10 will be assessed.

Baseline
28-Day All-Cause Mortality in Participants With HBV-ACLF
Ramy czasowe: From baseline through Day 28

Vital status and date of death will be determined from medical records and, when necessary, telephone follow-up. Liver transplantation will be recorded separately and will not be counted as death.

From baseline through Day 28
90-Day All-Cause Mortality in Participants With HBV-ACLF
Ramy czasowe: From baseline through Day 90

Vital status and date of death will be determined from medical records and, when necessary, telephone follow-up. Liver transplantation will be recorded separately and will not be counted as death.

From baseline through Day 90
Change in Plasma IL-33 Concentration in Participants With HBV-ACLF
Ramy czasowe: Baseline, Day 28, and Day 90

Plasma IL-33 concentration will be measured by ELISA at baseline, Day 28, and Day 90. Within-participant changes over time will be described and analyzed using repeated-measures methods specified in the protocol.

Baseline, Day 28, and Day 90
Change in ACOD1 mRNA Expression in Peripheral Blood CD14-Positive Monocytes in Participants With HBV-ACLF
Ramy czasowe: Baseline, Day 28, and Day 90

ACOD1 mRNA relative expression in peripheral blood CD14-positive monocytes will be measured by quantitative PCR at baseline, Day 28, and Day 90, using GAPDH as the reference gene and the 2^-DeltaDeltaCt method.

Baseline, Day 28, and Day 90
Change in MARCO mRNA Expression in Peripheral Blood CD14-Positive Monocytes in Participants With HBV-ACLF
Ramy czasowe: Baseline, Day 28, and Day 90

MARCO mRNA relative expression in peripheral blood CD14-positive monocytes will be measured by quantitative PCR at baseline, Day 28, and Day 90, using GAPDH as the reference gene and the 2^-DeltaDeltaCt method.

Baseline, Day 28, and Day 90

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

30 listopada 2026

Zakończenie podstawowe (Szacowany)

31 maja 2027

Ukończenie studiów (Szacowany)

31 października 2027

Daty rejestracji na studia

Pierwszy przesłany

15 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

15 listopada 2026

Pierwszy wysłany (Rzeczywisty)

19 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

19 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

15 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • ZZLX2026052

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .